Paloma Partners’s Intersect ENT, Inc XENT Stock Holding History

Paloma Partners’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,244	Closed	-$183K	–	2413
2020 Q3	$183K	Buy	+11,244	New	+$204K	﹤0.01%	1793
2020 Q1	–	Sell	-16,077	Closed	-$401K	–	2299
2019 Q4	$401K	Buy	+16,077	New	+$326K	0.01%	1549
2016 Q1	–	Sell	-9,485	Closed	-$213K	–	2141
2015 Q4	$213K	Buy	+9,485	New	+$188K	0.01%	1519

Other funds holding XENT

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Paloma Partners's XENT Position: Q4 2020 in Review

Paloma Partners sold out of Intersect ENT, Inc (XENT) in Q4 2020, closing a stake of 11,244 shares — an estimated $183K sold.

Paloma Partners first reported a position in XENT in Q4 2015 and held it in 3 quarters. The position peaked at $401K in Q4 2019. 110 funds tracked by Wall St. Rank hold XENT as of Q4 2020.

Paloma Partners reported no remaining Intersect ENT, Inc position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 11,244 Intersect ENT, Inc shares in Q4 2020, an estimated $183K.
Paloma Partners first reported a position in Intersect ENT, Inc in Q4 2015 and held it in 3 quarters.
Paloma Partners's Intersect ENT, Inc position peaked at $401K in Q4 2019.
110 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.